poisar

Stocks · News reference

Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19

Benzinga Newsdesk

Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REPL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Bragar Eagel & Squire, P.C.

    REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

    A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026.

    REPL
  4. SEC EDGAR

    8-K filing — Replimune Group, Inc. (REPL)

    Filed: 2026-09-16 AccNo: 0001104659-26-108243 Size: 215 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

    REPL